Loading clinical trials...
Loading clinical trials...
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
BT062 , intravenous administration
Locations
10
United States
City of Hope
Duarte, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Mayo Clinic
Jacksonville, Florida, United States
Memorial Healthcare System
Pembroke Pines, Florida, United States
Emory University Winship Cancer Institute
Atlanta, Georgia, United States
The University of Chicago
Chicago, Illinois, United States
Start Date
July 3, 2012
Primary Completion Date
October 30, 2018
Completion Date
October 30, 2018
Last Updated
July 23, 2019
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Biotest Pharmaceuticals Corporation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions